Biomarkers of blood–brain barrier and neurovascular unit integrity in human cognitive impairment and dementia

Биомаркеры целостности гематоэнцефалического барьера и нейроваскулярной единицы при когнитивных нарушениях и деменции у человека
Scott R. French, Briana P. Meyer, Juan C. Arias, Swati Rane Levendovszky, Craig C Weinkauf
2025-03-01

Alzheimer's disease and related dementiasblood-brain barrier dysfunctioncerebrospinal fluid biomarkersfluid biomarkersneurovascular unit integrity
Blood-brain barrier (BBB) dysfunction is recognized as an early step in the development of Alzheimer's disease and related dementias (ADRD). Biomarkers are needed to monitor BBB integrity over time, better understand the role of the BBB in neurodegeneration, potentially help define long-term ADRD risk, and monitor effects of therapeutics. In this review, we discuss the current biomarkers used to detect human BBB dysfunction in the context of cognitive decline and dementia. We also discuss promising candidate fluid biomarkers to detect BBB dysfunction in blood. HIGHLIGHTS: BBB permeability occurs during normal aging and is further exacerbated in ADRD. In this review, we discuss in vivo imaging and CSF biomarkers of BBB dysfunction currently used in the setting of aging and ADRD in humans. We also review promising candidate blood-based biomarkers that may represent BBB dysfunction.
1
BBB biomarkers could support understanding neurodegeneration, estimating long-term dementia risk, and monitoring therapeutic effects.
2
BBB permeability occurs during normal aging and is further exacerbated in Alzheimer’s disease and related dementias.
3
Blood–brain barrier dysfunction is recognized as an early event in the development of Alzheimer’s disease and related dementias.
4
Human in vivo imaging and cerebrospinal fluid biomarkers are currently used to assess BBB dysfunction in aging and dementia.
5
Promising blood-based fluid biomarkers may enable less invasive detection and longitudinal monitoring of BBB dysfunction.

The human blood–brain barrier and neurovascular unit in the context of cognitive impairment, normal aging, and Alzheimer’s disease and related dementias

Biomarkers and biomarker-based assessment of blood–brain barrier and neurovascular unit integrity and dysfunction, including imaging, CSF, and blood-based measures

Publication Details
Publication Date
2025-03-01
Journal
Publisher
ISSN
Access Type
Author Information
Authors
Scott R. French
Briana P. Meyer
Juan C. Arias
Swati Rane Levendovszky
Craig C Weinkauf
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%